Strategic partnerships Eurofins Discovery has a history of collaborating with pharma and biotech companies (e.g., Dompé, Awakn Life Sciences, Graft Polymer) and recently acquired Beacon Discovery. This signals openness to joint development programs and expansion of discovery capabilities, presenting opportunities to propose integrated drug discovery services and co-development pilots with potential clients in need of comprehensive platforms.

AI and NAMs Recent initiatives highlight a focus on New Approach Methodologies and AI-driven drug discovery through DiscoveryAI SAFIRE and partners leveraging AI platforms. Sales opportunities exist to offer in silico ADMET prediction, data science collaboration, and AI-powered screening to accelerate candidate selection for biotech firms exploring digital transformation.

Integrated platform DiscoveryOne and the combined strength with external AI infrastructure suggest Eurofins Discovery positions as a one-stop solution for discovery services. Target prospects could be organizations seeking end-to-end workflows from target validation through preclinical pharmacology, enabling cross-sell of testing services, data analytics, and integrated project management.

Global capabilities With a global team and multi-year experience in supporting drug discovery, Eurofins Discovery can offer scalable services to mid-market and emerging biotechs pursuing rapid expansion. Opportunities exist to customization and regional partnerships, as well as joint bids for multinational programs requiring standardized, compliant testing across jurisdictions.

Growth and footprint Revenue size and recent expansions, including acquisitions and new client wins, indicate a growth trajectory and capacity to take on larger, more complex projects. This presents sales potential for larger engagements, program expansions with existing clients, and cross-sell of new tools like SAFIRE into ongoing discovery workflows.